Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732848 · ClinicalTrials.gov registry record
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 113
- Enrollment target
NCT01732848: Completed study, sponsored by Bristol-Myers Squibb.
NCT01732848 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 113 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01732848 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 113 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials
Interventions
- DRUG BMS-986094/INX-08189
- DRUG Placebo matching BMS-986094/INX-08189
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
What the finished NCT01732848 record still lists
NCT01732848 is an observational study that tracks outcomes without assigning an intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which BMS-986094/INX-08189 is the first listed.
NCT01732848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01732848 about?
NCT01732848 is a clinical study titled "A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)". The purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials
What is the current status of trial NCT01732848?
This trial is currently completed. The enrollment target is 113 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01732848?
The interventions under investigation include: BMS-986094/INX-08189 (DRUG), Placebo matching BMS-986094/INX-08189 (DRUG).
Who is sponsoring clinical trial NCT01732848?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia